Compare SBSW & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBSW | AXSM |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 9.0B |
| IPO Year | N/A | 2015 |
| Metric | SBSW | AXSM |
|---|---|---|
| Price | $14.89 | $164.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 17 |
| Target Price | $16.28 | ★ $209.18 |
| AVG Volume (30 Days) | ★ 6.1M | 537.0K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.42 | $61.00 |
| Revenue Next Year | N/A | $54.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $86.99 |
| 52 Week High | $21.29 | $191.50 |
| Indicator | SBSW | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 34.76 |
| Support Level | $14.73 | $148.14 |
| Resistance Level | $15.83 | $191.13 |
| Average True Range (ATR) | 0.77 | 5.93 |
| MACD | -0.09 | -2.73 |
| Stochastic Oscillator | 24.24 | 14.02 |
Sibanye Stillwater Ltd is a South African mining and metals processing group with a diverse portfolio of operations, projects, and investments across five continents. The Group is also one of the foremost recyclers of PGM autocatalysts and has interests in mine tailings retreatment operations. It is a producer of platinum, palladium, and rhodium and is a top-tier gold producer. It also produces and refines iridium and ruthenium, nickel, chrome, copper, and cobalt. Its products are Gold, Nickel, Zinc, Chrome, PGMs, and other.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.